4.7 Article

Targeting ubiquitin in cancers

Journal

EUROPEAN JOURNAL OF CANCER
Volume 42, Issue 18, Pages 3095-3102

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.05.041

Keywords

ubiquitin; multiple myeloma; leukaemia; lymphoma; bortezomib; Ub system-targeted drugs

Categories

Ask authors/readers for more resources

Ubiquitin (Ub) is a small protein modifier involved in cellular functions such as cell cycle, apoptosis, cell signalling, endocytosis, transcription and DNA repair. Ubiquitin operates as a reversible and highly versatile regulatory signal, which may be read and interpreted by an expanding number of Ub-binding domains (UBD). There is accumulating evidence that mutations or altered expression of ubiquitylating or de-ubiquitylating enzymes as well as of Ub-binding proteins affect crucial mediators of such functions and are found in several malignancies. Here we discuss how oncogenic alterations in the Ub system can be targeted by anti-cancer therapies. (c) 2006 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available